Immunotherapy
Conference Coverage
Skin plus GI adverse events with checkpoint inhibitors linked to risk of additional adverse events
MILAN – Toxicities occurred early in treatment, and having both increased risk of adverse events in other organ systems.
Conference Coverage
EULAR issues guidelines on managing rheumatic complications of cancer immunotherapies
The new guidelines are tailored for rheumatologists, and address diagnosis and treatment.
Conference Coverage
Adjuvant immunotherapy results ‘encouraging’ in early NSCLC
CHICAGO – About one-fifth of patients with resectable non–small cell lung cancer had major pathological responses with atezolizumab monotherapy...
From the Journals
Checkpoint inhibitor rechallenge is possible for select patients
Rechallenge resulted in the recurrence of a grade 2 or higher immune-related adverse event (irAE) in 55% of rechallenged patients, but no deaths...
Conference Coverage
Low intensity bridging may be best path to CAR T in adult ALL
CHICAGO – Researchers examined the use of high- and low-intensity chemotherapy bridging for patients waiting for treatment with a CD19-directed...
From the Journals
Novel anti-PD-1 antibody can be given subcutaneously
“Subcutaneous administration of an anti-PD-1 antibody in patients with advanced solid tumors appears to be feasible,” the investigators wrote.
Clinical Review
Advanced Melanoma: Treatment After Progression on First-line Therapy
Clinical Review
Advanced Melanoma: First-line Therapy
Feature
ICYMI: NIH renames, streamlines gene therapy committee
The Recombinant DNA Advisory Committee will now be known as the Novel and Exceptional Technology and Research Advisory Committee.
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
Conference Coverage
Factors emerge for mitigating CD19 CAR T toxicity
HOUSTON – Cytokine release syndrome and neurotoxicity are common complications related to CD19-directed CAR T-cell immunotherapies, but research...